Established in 1968 by French vet Pierre-Richard Dick, Virbac provides biological and pharmaceutical products for veterinary and animal health use and is one of the 10 biggest veterinary pharmaceutical companies in the world. Products include vaccines, flea treatments, wormers, and antibiotics for animals. With some 20 subsidiaries (including US-based Virbac Corporation), the company's products are sold in more than 100 countries. Virbac's companion animal segment (dogs, cats, horses) represents more than 60% of the company's sales, while its food-producing animal segment (cows, chickens, cattle) brings in about 37%. The founding Dick family owns about 50% of the company.

Pacira Pharmaceuticals, Inc. company develops sustained-release therapies based on DepoFoam, an injectable drug delivery technology that allows both immediate and sustained release. Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain. Pacira's lead candidate is EXPAREL, an injectable local anesthetic. The company has two manufacturing facilities that make its Depo products. Once the injectables subsidiary of drug-delivery company SkyePharma PLC, Pacira was bought out in 2007 by an investor group led by MPM Capital, OrbiMed, HBM Bioventures, and Sanderling Ventures.

American Bio Medica Corporation develops, manufactures, and sells immunoassay diagnostic test kits for the point of collection testing (POCT) for drugs of abuse in North America, Europe, the Asia/Pacific Rim, Africa, and South America. Its products include Rapid Drug Screen, a POCT kit to detect the presence or absence of 2 to 10 drugs of abuse in a single urine specimen; Rapid One, which screens for the presence or absence of a single drug of abuse in a urine specimen; Rapid TEC that contains 1 or 2 drug testing strips to test for 2 to 5 drugs of abuse in a single urine specimen; RDS InCup, a POCT for 2 to 12 drugs of abuse that incorporate collection and testing of sample in a device; Rapid TOX, a drug screen that detects 2 to 10 drugs of abuse in a single urine specimen; and Rapid TOX Cup, a POCT for 2 to 14 drugs of abuse that incorporate collection and testing of sample in a single device.American Bio Medica Corporation company’s products also include OralStat, a POCT system to detect drugs of abuse in oral fluids; OralStat EX, an oral fluid POCT for point of collection testing and confirmation testing; and Rapid STAT, an oral fluid POCT. In addition, it offers Rapid Reader, a compact and portable device that captures a picture of the test results on an ABMC drug screen. Further, American Bio distributes various POCTs to detect the presence or absence of adulterants, alcohol, and nicotine; and provides bulk strip contract manufacturing services to non-affiliated POCT diagnostic companies. It offers products for employers, law enforcement, government, health care, laboratory, and education professionals to test for cocaine, THC, opiates, amphetamines, PCP, benzodiazepines, methamphetamines, barbiturates, tricyclic antidepressants, methadone, oxycodone, propoxyphene, and buprenorphine. The company was formerly known as American Micro Media, Inc and changed its name to American Bio Medica Corporation in September 1992. The company was founded in 1986 and is based in Kinderhook, New York.

Imperial Ginseng Products company cultivates more than 550 acres of North American ginseng root used in traditional Chinese medicine. The company operates a farm in Ontario, Canada, where the root is grown for three or four years (each year increases yield and value), harvested, and dried. Imperial Ginseng Products sells the dried root to buyers in North America and Asia, who then turn it into prepared remedies. CDS & Co owns 55% of the company, while co-chairmen Hugh Cartwright and Stephen McCoach and director Maurice Levesque together hold nearly 40%.

Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S. The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany.

Chugai Pharmaceutical develops therapies for bone metabolism and blood disorders, cancer, infectious diseases, immune system disorders, and cardiovascular, kidney, and brain diseases. Products include Neutrogin, which treats white blood cell loss related to chemotherapy; Epogin, which treats red blood cell loss caused by chronic kidney failure; Sigmart, an antianginal agent; and Alfarol for osteoporosis. Chugai Pharmaceuticals has foreign operations in Asia, Europe, and North America through subsidiaries and branch locations. Swiss drugs group Roche owns about 60% of Chugai Pharmaceutical.

Unigene Laboratories, Inc. company was founded in 1980 and is based in Boonton, New Jersey. Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptides for medical use primarily in the United States. The company focuses on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications, including nasal and oral calcitonin, and oral parathyroid hormone (PTH). It offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis. Unigene Laboratories has licensing agreements with GlaxoSmithKline to develop an oral formulation of an analog of PTH; Upsher-Smith Laboratories, Inc. to market Fortical; Novartis Pharma AG to manufacture calcitonin; and Shijiazhuang Pharmaceutical Group for research, development, and manufacture of recombinant salmon calcitonin and non-oral PTH.

Janssen has gone totally mental. A US-based arm of Johnson & Johnson'sglobal pharmaceuticals segment, Janssen focuses exclusively on treatments for mental health conditions. Its flagship offering Risperdal combats bipolar mania and schizophrenia, as well as irritability associated with autism. A long-acting injectable version of the drug, called Risperdal Consta, is approved as a treatment for schizophrenia. With its sister company Johnson & Johnson Pharmaceutical Research & Development, the company is working on potential drugs for a range of psychiatric problems, including psychosis, sleep disorders, attention deficit/hyperactivity disorder, depression, and substance abuse.

NutraCea is a health science company that has intellectual property that allows the Company to process and convert rice bran into a nutritious ingredient, stabilized rice bran that has applications in various food products and as components of formulations that have applications for treatment modalities in nutritional supplementation. It is also used as a stand-alone product that can be sold through non-related entities with distribution into the market place, both in the United States and internationally. These products include food supplements and medical foods. The Company operates in two segments: the NutraCea segment, which manufactures and distributes ingredients primarily derived from SRB, and the Irgovel segment, which consists of its rice-bran oil and fatted and de-fatted SRB manufacturing subsidiary in Pelotas, Brazil. In November 2009, the Company filed a voluntary petition for protection under Chapter 11 of the United States Bankrupt Code.

Ricerca Biosciences LLC company provides one stop shopping of pharmacology and toxicology, medicinal chemistry, drug substance synthesis, and preclinical and clinical development for small to medium pharmaceutical companies looking to bring drugs to market. The contract research organization (CRO) also offers regulatory filing and report writing services. Ricerca Biosciences provides expanded services through partnerships with companies such as Bicoll Group, Latitude Pharmaceuticals, and Xcelience Formulation Development.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.